{"id":"W2537692172","doi":"10.1200/jco.2013.31.6_suppl.lba8","title":"Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Docetaxel; Dasatinib; Clinical endpoint; Internal medicine; Prostate cancer; Hazard ratio; Urology; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Gastroenterology; Cancer; Tyrosine kinase; Clinical trial; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005289626,0.0002058764,0.002461113,0.00009804282,0.00005870522,0.00002409224,0.0001519287,0.0001471431,0.000158429],"category_scores_gemma":[0.005151314,0.00009649874,0.0002510595,0.0001622172,0.0006174875,0.0002168598,0.00004453973,0.0007897443,0.000002661344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001728964,"about_ca_system_score_gemma":0.00206267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002235783,"about_ca_topic_score_gemma":0.0007400162,"domain_scores_codex":[0.9937593,0.001531051,0.003420308,0.0002733154,0.0007215868,0.0002944734],"domain_scores_gemma":[0.9842337,0.01171283,0.002600829,0.0002574159,0.000903634,0.0002915938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9709086,0.002703419,0.005694582,0.00002192793,0.001574189,0.00008484391,0.0005164479,0.00001708126,0.00004429934,0.00004088923,0.0007269516,0.01766679],"study_design_scores_gemma":[0.8888499,0.01643145,0.0920782,0.0001963882,0.0008797774,0.00000214074,0.000246672,0.00009385093,0.00002467632,0.0001911825,0.0009150727,0.0000907553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98861,0.0007230732,0.000006897977,0.006363852,0.0006859779,0.002729242,0.0002097263,0.000003905188,0.0006672967],"genre_scores_gemma":[0.9954656,0.002743476,0.0008384622,0.0002082036,0.0002973521,0.00006793933,0.00008296457,0.00001763089,0.000278401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08638362,"threshold_uncertainty_score":0.6166975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1351763167605917,"score_gpt":0.4676910722699166,"score_spread":0.3325147555093249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}